Before You Invest:
5 Steps to Verify An Effective VNS Device

Step 1. Check if target area actually reaches the Vagus Nerve

Ear, neck, chest, wrist, foot... access matters

Device targets the only proven surface-level Vagus Nerve endings - the ear's tragus

In The Great Nerve, Dr. Kevin Tracey (leading Vagus Nerve researcher) explains that the cymba conchae and the ear's tragus are the only places on the human body where the vagus nerve endings actually travel to the surface of the skin:

"It’s the only place that the vagus nerve endings go to the surface of the skin, and they are sensory."

Target Site
Anatomical Validity
Research Volume
Scientific Mechanism
Effectiveness
Target Site Foot
Anatomical Validity None
Research Volume None
Scientific Mechanism No direct vagal innervation; relies on general relaxation or placebo.
Effectiveness Ineffective
Target Site Wrist
Anatomical Validity None
Research Volume None
Scientific Mechanism Targets peripheral nerves (Median/Ulnar) which do not have a direct Vagus connection.
Effectiveness Ineffective
Target Site Chest
Anatomical Validity Low
Research Volume None
Scientific Mechanism Claims "vibrational" or "magnetic" reach, but lacks direct electrical nerve contact.
Effectiveness Unproven
Target Site Neck (Cervical)
Anatomical Validity Low (for consumer tech)
Research Volume Low (for consumer tech)
Scientific Mechanism Extremely hard to stimulate the vagus accurately or go deep enough without surgery. A site used invasively because there is space to wrap an electrode around the nerve with device implant in torso.
Effectiveness Risky (Electricity can spill to nearby nerves, causing involuntary voice changes, neck muscle twitching, or sudden heart rate/BP drops.)
Target Site Ear Tragus
Anatomical Validity High
Research Volume Extensive
Scientific Mechanism Direct access to the Auricular Branch of the Vagus Nerve (ABVN); sends signals to the Brainstem (NTS).
Effectiveness Proven
Target Site Ear (Non-Tragus)
Anatomical Validity Low
Research Volume Minimal
Scientific Mechanism Targets areas innervated by the Great Auricular or Occipital nerves, not the Vagus.
Effectiveness Unproven

Nurosym AVNT™ is a medical-grade device undergone safety and quality checks, and regulatory compliance

  • Nurosym AVNT™ modulates key brainstem centres via the auricular branch of the vagus nerve located in the ear's tragus - the primary anatomical gateway for non-invasive Vagus Nerve Stimulation
  • 67% increase in vagus nerve activity after 5 minutes reported in third-party clinical study populations
  • 90% increase in vagus nerve activity after 2 months reported in third-party clinical study populations
Shop Nurosym

Attention: Read further cautionary notes

Step 2. Check if the stimulation method is effective

The body speaks one language - electricity

Prioritize bioelectricity and neuromodulation-based devices

The field of neuromodulation is built on the fact that the nervous system speaks a language of electrical impulses. 
Electrical VNS is the only method with decades of peer-reviewed clinical data proving it can physically depolarize the vagus nerve and trigger a response in the brainstem.

Method
Scientific Category
Research Level
Mechanism of Action
Proven to Reach Brain?
Method Electricity
Scientific Category Neuromodulation
Research Level Gold Standard
Mechanism of Action Direct depolarization of the nerve via electrical current; mimics natural bioelectric signals.
Proven to Reach Brain? Yes
Method Vibration
Scientific Category Mechanical Stimulation
Research Level Low
Mechanism of Action Uses kinetic energy to shake tissue; relies on "bone conduction" or skin receptors.
Proven to Reach Brain? Inconclusive
Method Sound
Scientific Category Acoustic / Sensory
Research Level Low
Mechanism of Action Relies on the "Vagus Nerve-Ear" connection through audio frequencies or "binaural beats."
Proven to Reach Brain? No
Method Magnetic
Scientific Category Electromagnetic
Research Level Moderate
Mechanism of Action Uses magnetic fields to induce electrical current deep within the tissue (TMS style).
Proven to Reach Brain? Likely (Hard to target)
Method Manual (Massage)
Scientific Category Physical Manipulation
Research Level Low
Mechanism of Action Applying pressure to the neck or ear to manually compress the nerve.
Proven to Reach Brain? Temporary / Indirect

Nurosym AVNT™ sends gentle bioelectronic impulses with precisely controlled frequency and intensity

  • Nurosym AVNT™ was empirically researched for 10+ years to achieve a proprietary waveform with effective and precise downstream effects, co-developed by leading neuroscientists, neurologists and researchers to ensure high efficacy while minimizing side effects
  • Nurosym AVNT™ - similar to how a pacemaker regulates the heart - sends electrical signals to specific vagus nerve fibers to restore normal nervous system function
Shop Nurosym

Attention: Read further cautionary notes

Step 3. Check for clinical-grade, quantifiable scientific proof

3.1 Third-party clinical trials

Look for rigorous third-party clinical trials independently led by reputable institutions

The most reliable signal of effectiveness is a body of research conducted by independent universities or hospitals, rather than studies funded and managed entirely by the manufacturer. Third-party validation ensures that the results haven't been "cherry-picked" to favor the device.

3.2 Randomized Placebo-controlled Studies

Look for the Gold Standard in trial design - Randomized Placebo-Controlled Studies

Effectiveness is only proven if the device can outperform a "sham" or placebo treatment. In high-quality VNS research, the control group receives a sensation that feels like stimulation but doesn't actually target the nerve; if the real device doesn't show significantly better results than the sham, the technology is likely ineffective.

3.3 Statistically significant results

Verify statistically significant results across diverse populations in real-world conditions

High-tech devices should demonstrate consistent efficacy across different ages, genders, and health profiles. If a device was only tested on a tiny, specific group of people, its technology may not be robust enough to work for the general population. Verify effectiveness is proven when a device works under real-world conditions. Seek out data that shows the device remains effective during daily stressors, not just while a subject is sitting perfectly still in a controlled clinical environment.

3.4 Quantifiable physical results, not surveys

Clinical results are focused on hard physiological biomarkers and proven symptom scoring systems

Clinical results must be based on a number of quantifiable physiological data biomarkers and not relying on subjective self-report alone. Be wary of devices that rely solely on "subjective self-reports" (e.g., "I feel 20% more relaxed"). A top-tier device will back its claims with quantifiable data, such as improvements in Heart Rate Variability (HRV), reduced cortisol levels, or suppressed inflammatory cytokines. Precise measuring includes wearable or implantable monitors, numerous biomarkers and validated symptom scores — rather than relying on subjective self-report alone.

SCIENTIFIC EVIDENCE

Nurosym breakthrough research at a glance

Nurosym AVNT™ is the first clinically proven CE-marked non-invasive vagal neuromodulation system in collaboration with leading institutions

Nurosym breakthrough research at a glance

150+

Research partners including Harvard, UCLA, and NHS Trusts.

1000+

Licensed healthcare professionals recommend Nurosym

60+

Clinical studies including placebo-controlled trials and peer-reviewed publications

10+

Years of iterations by Parasym lab R&D with patented technology

Step 4. Check if device meets medical device standards

4.1 Regulatory safety approval is non-negotiable

Device is CE-marked in Europe under EU Medical Device Regulation (MDR)

A "CE mark" on a VNS device is not just a sticker; it is a legal certification that the manufacturer has complied with the EU Medical Device Regulation (MDR). This signals that the device has undergone rigorous testing for electrical safety, biocompatibility (ensuring the electrodes don't irritate your skin), and technical performance.

4.2 Medical-grade device

Make absolutely certain this is a "medical-grade" device

Distinguish Between "Consumer" and "Medical" Grade. Many low-end stimulators are sold as "general wellness" products to avoid regulatory scrutiny. A high-tech VNS device will be classified specifically as a Class IIa medical device (or higher), meaning it is legally cleared to treat specific conditions like anxious thoughts or depressive states rather than just being a "massager."

It is also critical to distinguish between actual medical certifications and the common FCC mark, which merely regulates radio interference; any device touting an FCC label as proof of health efficacy is essentially using a basic electronics requirement to mask a lack of clinical validation.

4.3 Good Clinical Practice compliance

Verify GCP (Good Clinical Practice) Compliance

Look for devices whose clinical trials were conducted under GCP standards. This is an international ethical and scientific quality standard that ensures the rights and safety of participants were protected and that the resulting data is credible. If a device lacks GCP-compliant research, its safety and effectiveness claims are technically unverified.

Nurosym AVNT™ is a medical-grade device undergone safety and quality checks, and regulatory compliance

  • Nurosym AVNT™ is CE-marked non-invasive wearable device under the European Medical Device Directive (MDD), this certification ensures the device meets EU standards for safety, performance, and clinical benefit
  • Nurosym AVNT™ research is conducted under ICH-GCP guidelines and regulations ensuring rigorous protocol design, ethical integrity, data reliability, and participant safety.
Shop Nurosym

Step 5. Check for must-have features and fair pricing model

5.1 Signal modulation and customization feature

Device has the ability to regulate intensity

Not all levels of stimulation are good for you. Like tuning a radio to the right signal, vagus nerve stimulation needs to be adjusted to each person's unique nervous system. The optimal settings vary day by day and between individuals.

Excessive or imprecise stimulation can disrupt the nervous system and cause harmful side effects, even leading to permanent damage. Beware of low-end devices using "dirty" signals that can cause skin irritation or "nerve fatigue." High-end tech provides a "clean," consistent pulse that targets the nerve without collateral sting.

5.2 Unlock and use without apps, subscriptions

Device can unlock without mobile app, there's no monthly subscription

A major signal of a "consumer trap" is a device that requires a monthly fee to remain functional or requires. High-quality VNS technology should be a one-time investment; once you own the hardware, you should have full access to the stimulation programs required for your health.

Be wary of companies that sell you the hardware but "lock" treatment options or data tracking behind a premium subscription. This practice signals that the company is prioritizing a recurring revenue model over your long-term clinical outcome and may even be trading away your health data to monetize further and boost their bottom line.

5.3 Special gels or liquids

There's no extra costs for special conductivity gel or liquid

Gel is not only messy, annoying and unpleasant - it can be a costly trap. The requirement to purchase a proprietary gel is often less about science and more about 'locking' you into a subscription. It’s a classic formula to turn a one-time purchase into a lifetime of forced refills.

In reality, most high-end medical-grade tech is moving toward dry-contact electrodes. If you do need to boost conductivity, don't fall for the 'brand-only' trap; standard water-based alternatives—or even a simple dampen of the skin—often provide the same results without the mess or the markup.

5.4 Lifestyle integration and accessibility features

Device doesn't demand my full attention while using, I'm free to do other things

Some VNS devices are designed to limit you completely which is not ideal for 20-60m sessions every day. Be careful since such devices may create "therapy fatigue." High-tech devices prioritize wearability, allowing you to stimulate the vagus nerve while walking, working, or commuting.

The gold standard for accessibility is a hands-free interface that allows you to receive the treatment "passively" while going about your day.

Nurosym AVNT™ is a standalone device featuring precise intensity controls and an ergonomic, accessible design

  • Nurosym AVNT™ comes without any subscription with the only ongoing cost being the earpiece, which depending on usage lasts 18 months on average.
  • Nurosym AVNT™ provides up to 45 precise stimulation levels that allow users to tune to the exact intensity their body needs on that day, at that time.
  • Nurosym AVNT™ is designed for accessibility, requiring zero mental effort so you can seamlessly integrate sessions into your daily routine during non-intensive activities.
Shop Nurosym

Bonus Checks: Are there discreet signs it is a medical-grade instrument

Medical devices are not gimmicky and don't have recreational features

Device doesn't look like a toy and is not used for fun

High-tech VNS devices are precision instruments designed for neuromodulation, not entertainment. If a device includes "recreational" features—like built-in music players, RGB mood lighting, or gamified "badges"—it is often a signal that the product is a consumer toy rather than a medical-grade tool.

Extra points if you assess the marketing language. High-tech brands speak in terms of "pathways," "inflammation," and "neuromodulation." Gimmicky brands use vague, recreational terms like "vibes," "biohacking," or "bio-harmony." If the language leans too heavily on "recreational wellness" buzzwords, it’s likely because they lack the clinical expertise to speak in medical terms.

Dr. Bandera Explains: The 5 Fatal Mistakes to Avoid Before Investing In A VNS Device

Ready to see why 1000+ experts recommend Nurosym?

How does Nurosym Work

The Mechanisms of Nurosym Neuromodulation

Nurosym sends patented electrical impulses to the brain via the Vagus Nerve, which leads to:

61% increase in Vagus Nerve Activity & 18% Improved Heart Rate Variability

61% increase in Vagus Nerve Activity & 18% Improved Heart Rate Variability

Stress Management Depression & Anxiety Reduction Sleep Quality Exercise Recovery Anti-ageing & Longevity Autonomic Balance

The parasympathetic nervous system is the body’s internal relaxation & rest mechanism. HRV is an indicator of Vagus Nerve activity. Improving these parameters of HRV indicates targeted stimulation of the vagus nerve and activation of specific self-repair mechanisms of body & mind. In a clinical trial, a one-hour session of Nurosym favourably altered all three parameters of Heart Rate Variability (HRV), when compared to a placebo. Figure (a) shows High Frequency HRV is significantly increased ('p=0.001). Figure (b) shows Low-Frequency HRV is significantly decreased ('P=0.001). Figure (c) shows the ratio of LF to HF is significantly decreased (*p=0.002).

35% reduction in anxious thoughts

35% reduction in anxious thoughts

Stress Management Anxious thoughts relief Insomnia Resilience Performance Inflammation Control Cortisol Control

Studies have demonstrated that pre-existing symptoms such as anxious thoughts further heighten the risk of symptoms associated with chronic inflammation. Research on the Nurosym neuromodulation system has shown that it activates the vagus nerve, leading to a reduction in anxious thoughts and stress responses. This targeted stimulation of the vagus nerve increases vagal tone and inhibits cytokine production in the inflammatory process. Both are important mechanisms for anxious thoughts management and resilience. The figure illustrates changes in anxiety across three timepoints: pre-intervention (D0), post-intervention (D10) (D0 vs D10, p < 0.001), and 1-month follow-up after accomplished therapy (D0 vs Follow-up, p < 0.001).

48% reduced Fatigue & increased Energy

48% reduced Fatigue & increased Energy

Productivity Social Functioning Brain Fog Reduction Sleep Quality Pain Relief Long-Covid Symptoms Ageing & Longevity

Nurosym neuromodulation has demonstrated a beneficial effect on fatigue by modulating the autonomic nervous system, leading to enhanced energy levels and reduced sensations of exhaustion. In the study, patients reported sustained improvements even one week after discontinuing the therapy, indicating prolonged relief from fatigue-related symptoms.(Figure) Fatigue was assessed using the Pichot fatigue scale scores during therapy (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% improvement (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation therapy.

31% improvement in Sleep Scores

31% improvement in Sleep Scores

Insomnia Reduction Fatigue Improvement Immune Function Metabolic Health Memory Ageing & Longevity

In individuals with sleep onset difficulties, the sympathetic branch of the autonomic nervous system may exhibit heightened activity compared to the parasympathetic branch, resulting in increased agitation. The study demonstrated that Nurosym neuromodulation enhances parasympathetic activity, which in turn mitigates agitation and improves sleep scores. (Figure) Changes in sleep (PSQI Sleep Disturbance Score) across three timepoints: pre-intervention, 2-weeks, and 4-weeks (*p < 0.05).

80% reduction in digestive issues

80% reduction in digestive issues

The vagus nerve serves as the primary communication highway between your brain and your gastrointestinal tract. When chronic inflammation or lingering post-viral interference disrupts this critical vagal-gut axis, it can trigger severe, persistent digestive problems and gut dysfunction.

In clinical evaluations of Nurosym neuromodulation, patients receiving Auricular Vagal Neuromodulation Therapy experienced a dramatic 80% reduction in the frequency of their gastrointestinal symptoms.

The figure presents the significant decrease in the frequency of reported digestive issues before and after the targeted neuromodulation therapy.

78% reduction in inflammatory markers

78% reduction in inflammatory markers

Inflammatory Processes Aging & Longevity Muscle Pain Chronic Pain Cardiac Conditions (AF HF Hypertension) Mental Health Autoimmune Disorders IBS & Other GI Symptoms

Inflammation throughout the body and brain contributes to disease development, progression, ageing, and mental health problems. In a randomised controlled trial of Nurosym neuromodulation, inflammatory cytokines were significantly lower in the group that received Auricular Vagal Neuromodulation Therapy (AVNT) compared to the placebo group at the end of 3 months.(Figure) The figure presents the changes in the IL-6 inflammatory biomarker compared to placebo.

61% improved Brain Fog, Gastrointestinal Function & Pain (Post-viral Fatigue Symptoms)

61% improved Brain Fog, Gastrointestinal Function & Pain (Post-viral Fatigue Symptoms)

Chronic Fatigue Syndrome (ME/CFS) Stress & Anxiety Management Mental Health Athletic Recovery Productivity Respiratory Improvement Gastrointestinal & IBS Control

A growing body of research suggests that vagus nerve regulation plays a crucial role in managing chronic inflammation. Nurosym, through the stimulation of afferent vagus nerve fibres, has been shown to influence higher brain structures. This modulation may help alleviate symptoms connected to Post-viral Fatigue Syndrome such as chronic fatigue, pain, and brain fog.(Figure ) A very significant improvement in Post-viral Fatigue symptoms was observed after 10 neuromodulation therapy sessions. (D0 vs. D10: p < 0.0001).

45% improvement in Depressive States & Improved Mood

45% improvement in Depressive States & Improved Mood

Cognitive Improvement Mood Stabilisation Stress Resilience Brain Fog Sleep Quality: Post-Traumatic Recovery

Disruption of signals in the afferent fibres of the vagus nerve can directly or indirectly induce brain disorders, including depressive states. Nurosym neuromodulation significantly decreased depressive state scores and improved mood within just 5 days of therapy, with continued improvement observed after 10 days.(Figure) The figure shows the evolution of the Beck depression scale (D0: day 0, D5: day 5 and D10: day 10). The results showed a noticeable improvement in mood, registering approximately 45% on the Beck Depression Scale (p<0.05).

11% improvement in Attention Deficiency Symptoms

11% improvement in Attention Deficiency Symptoms

Attention and Focus Behavioral Regulation Impulse Control Executive Function Emotional Regulation Social Interaction

Individuals with attention deficits, including those diagnosed with ADHD, often exhibit low heart rate variability (HRV) measurements, indicating reduced vagus nerve activity and diminished parasympathetic tone. Nurosym neuromodulation counteracts the persistent sympathetic "fight-or-flight" overdrive, thereby enhancing cognitive function.(Figure) Changes in attention were assessed using the Flanker Inhibitory Control and Attention assay across three timepoints: pre-intervention, post-intervention, and 1-month follow-up. After Nurosym therapy, significant gains were detected from pre-intervention to post-intervention (p < 0.01) and from pre-intervention to follow-up (p < 0.001).

40% reduction in postural heart rate abnormalities

40% reduction in postural heart rate abnormalities

Heart Rhythm Arrhythmias & Palpitations Control Dizziness Reduction Cardiovascular Health Exercise Tolerance Immune Function

People who suffer from postural heart rate abnormalities or tachycardia have diminished size vagus nerves. Research team discovered that postural heart rate abnormalities symptoms were significantly lessened in people receiving Nurosym — 15 beats less per minute compared to the placebo group. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR)(Figure) Comparison of Orthostatic Tachycardia between Nurosym neuromodulation and placebo stimulation after a 2-Month. The figure illustrates the changes in heart rate upon standing.

28% reduction in Oxidative Stress (Reactive Oxygen Species)

28% reduction in Oxidative Stress (Reactive Oxygen Species)

Aging & Longevity Inflammatory Processes Antioxidant Defense Cellular & Mitochondrial Function Oxidative Stress Markers Cortisol Levels

Biologically, the vagus nerve inhibits oxidative stress, inflammation and sympathetic activity (and associated hypoxia). Nurosym led to a significant decrease in reactive oxygen species (ROS) (p = 0.004), while placebo stimulation did not cause a significant change (p = 0.10).(Figure) Change in median DCF values from admission to discharge in the Nurosym group compared to the placebo group (p < 0.005).

29% improvement in Reading and Learning

29% improvement in Reading and Learning

Cognitive Enhancement Alzheimer’s & Dementia Brain Fog Mood Improvement Ageing & Longevity Social Functioning

Researchers have demonstrated a direct link between vagus nerve stimulation and the activation of learning centres in the brain. This discovery has led to the evaluation of Nurosym neuromodulation, which has been shown to enhance cognitive retention in both healthy individuals and those with injured nervous systems.(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performance on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.

32% improvement in Memory Recall

32% improvement in Memory Recall

Productivity Problem-Solving Skills Alzheimer’s & Dementia Cognitive Enhancement & Performance Social Functioning Memory function Post-Traumatic Recovery

The vagus nerve, through its physiological connections to various brain areas, plays a key role in modulating many behavioural processes related to memory. Nurosym research investigates enhancements in memory and neuroplasticity, linking cognitive function with the parasympathetic nervous system.(Figure A, B) Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.

85% reduction in Atrial Fibrillation Burden

85% reduction in Atrial Fibrillation Burden

Performance Productivity & Energy Reduced Cardiovascular Risks Cognitive Function Reduced Pain Arrhythmias Control Autonomic Balance

The vagus nerve modulates the inflammatory response, thereby reducing the systemic inflammatory burden that contributes to the progression of various diseases, including atrial fibrillation. Leveraging this mechanism, Nurosym neuromodulation offers a non-invasive modality for regulating cardiac rhythm, effectively suppressing atrial fibrillation.(Figure) Comparison of atrial fibrillation (AF) burden between the two groups (Nurosym neuromodulation vs Placebo stimulation) is presented using interquartile range values. The p-value reflects the comparison of median AF burden levels at the 6-month mark, adjusted for baseline measurements.

19% improvement of Heart Muscle Function (Global Longitude Strain reduction)

19% improvement of Heart Muscle Function (Global Longitude Strain reduction)

Heart Function Performance Productivity & Energy Reduced Heart Failure Risk Cardiovascular Improvement

Many studies have shown that drug treatments do not improve morbidity and mortality in patients after myocardial infarction. These patients often exhibit significant autonomic dysfunction, characterised by increased sympathetic nervous system activity and decreased parasympathetic (vagal) activity. The study found that Nurosym is effective by targeting cardiac inflammation and autonomic dysfunction. (Figure) Comparison of the effect of Nurosym neuromodulation on global longitudinal strain (GLS) during active versus placebo stimulation. Active neuromodulation resulted in a significant improvement in GLS (p = 0.001) compared to sham stimulation.

50% improvement in Blood Vessel Flexibility & improved Circulation (FMD)

50% improvement in Blood Vessel Flexibility & improved Circulation (FMD)

Blood Clots Risk Reduction Endothelial Function Peripheral Vascular Control Cognitive Enhancement Improved Metabolism Fatigue Reduction

The purpose of the study was to determine the influence of vagal innervation control of the resting diameter of large blood vessels using Nurosym neuromodulation. Nurosym has demonstrated a significant ability to enhance blood circulation and macrovascular endothelial function compared to a placebo.(Figure) Percent change in flow-mediated vasodilation (FMD) with Nurosym. "Before" and "after" refer to the brachial artery (BA) diameter and FMD test conducted pre- and post-Nurosym neuromodulation. The y-axis shows the percent change in BA diameter. The box shows the 25th–75th percentile, the middle line is the median, the dot is the mean, and the bars indicate the maximum and minimum values.

39% improvement in markers of Microcirculatory Function

39% improvement in markers of Microcirculatory Function

Cardiovascular Health Varicose Veins Organ Function Cognitive Enhancement Improved Metabolism Oxygen and nutrient delivery to tissues

Parasympathetic outflow utilises the circuit from the dorsal motor nucleus of the vagus nerve to regulate circulation. This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products. The study using Nurosym indicated a trend towards enhanced microcirculatory function,(Figure) (A) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation

34% improvement on Cardio-Vagal Baroreflex Gain

34% improvement on Cardio-Vagal Baroreflex Gain

Blood Pressure Regulation Heart Rate Stability Cardiovascular Adaptation Exercise Tolerance Fatigue Reduction

The use of Nurosym may positively influence cardio-vagal baroreflex gain (BRS) in patients with chronic heart failure (CHF). BRS, a marker of autonomic function, is often impaired in CHF, contributing to poor outcomes. Enhancing BRS through Nurosym could improve parasympathetic tone, stabilise cardiovascular regulation, and potentially mitigate disease progression. (Figure) Acute AVNT significantly increased cardio-vagal baroreflex gain in the study population, demonstrating its potential to enhance autonomic cardiovascular regulation in patients with chronic heart failure.

10% Reduction in Blood Pressure

10% Reduction in Blood Pressure

Reduced Cardiovascular Risk Systolic and Diastolic Control Reduced Stress Markers Cardiovascular Efficiency Quality of Life

Nurosym reduced systolic blood pressure (SBP) by approximately 9.7% and diastolic blood pressure (DBP) by 10.2% over three months in young adults with Grade 1 hypertension. Additionally, it significantly reduced stress markers and stabilised cardiovascular function by reducing vascular resistance without altering heart rate. Patients also reported improved quality of life, highlighting the intervention’s broader benefits.

Independent-led studies in collaboration with leading institutions

Our work is conducted in collaboration with leading research institutions who independently lead and fund the clinical trials across diverse clinical populations

Peer-reviewed studies

Scientific inquiry drives everything at Parasym. Our research strategy extends beyond individual conditions—we collaborate with leading health institutions to conduct rigorous, independent clinical trials evaluating the therapeutic potential of non-invasive vagal nerve stimulation across a spectrum of disorders.

We actively publish our findings in peer-reviewed medical journals in partnership with globally recognized researchers and HCPs. These publications contribute to the growing body of knowledge on autonomic dysfunction, chronic inflammation, and the field of bioelectronic medicine. Nurosym’s technology has been featured in over 50 peer-reviewed articles, including randomized controlled trials, mechanistic studies, and clinical reviews of auricular vagal stimulation.

Multiple clinical trials are currently in progress, with upcoming results. As new research is published, this section will be updated. Several manuscripts are also in development and will be submitted for peer review in the coming months.

Frontiers in Neurology

Clinical Trials

This study provides evidence supporting the potential of t-VNS as a therapeutic intervention for Long COVID patients. tVNS activated brainstem centers that regulate norepinephrine and acetylcholine release, improving neuroplasticity and cognitive control. Benefits in attention, processing speed, memory, mood, and sleep suggest broad modulation of brain–body circuits. The delayed fatigue improvement points to downstream effects on neuroinflammatory pathways.

Read paper
Frontiers in Neurology & Neuroscience

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long COVID Syndrome: A Pilot Study

tVNS dramatically reduced the severity of symptoms including fatigue, pain, digestive problems, dyspnea, and cognitive difficulties. long-COVID is linked to dysautonomia rather than persistent systemic inflammation. tVNS may act through a “sympathetic reset,” rebalancing autonomic function and alleviating symptoms.

Read paper
Clinical and Experimental Rheumatology

Reduction in anxious states

The study evaluated auricular vagal neuromodulation therapy in fibromyalgia (FM) patients. It demonstrated significant improvements in disease severity and sleep quality, with many patients no longer meeting FM diagnostic criteria after treatment. tVNS enhances parasympathetic tone and reduces autonomic dysfunction, which is thought to underlie FM symptoms such as pain, fatigue, and sleep disturbance.

Read paper

THE CHALLENGE

Not just mapping the nervous system. We’re learning to talk to it with scientific precision.

Neural Pathways and Potential Mechanisms Involved in Neuromodulation Using Low Level Tragus Stimulation

Potential-Mechanism Image
Potential-Mechanism mobile Image

Scientific Explanation

At the heart of Nurosym’s mission has been one central challenge - how to send bioelectrical signals that reach and activate precisely the right brain centers—without disturbing the rest.

Nurosym-placebo-image Nurosym-placebo-image
Dr. Elisabetta Burchi, MD, MBA

Meet the Doctors

A practicing doctor of psychiatry, Elisabetta has an MBA from INSEAD Business School, and experience in direct patient care, neuroscience research, communication and management. Dr. Burchi is a physician-scientist, working with Parasym in clinical affairs with a track record of publishing in the most important scientific journals such as The Lancet, writing successful grant proposals for the NIH, and leading the production of editorial, clinical, regulatory and promotional material in collaborative multidisciplinary teams. Dr. Burchi has also coordinated clinical trials and implemented a tele-medicine practice which received a certification of excellence among more than 100,000 professionals.

Dr. Elisabetta Burchi, MD, MBA
Translational research lead at Parasym

Collaborations

Are you a healthcare professional?

If you are a licensed healthcare practitioner or medical researcher click here to learn more about collaboration opportunities and exclusive access to scientific research.

Learn more

Upplev framtiden för bioelektronisk medicin

Få €70 rabatt på det mest studerade VNS-systemet

Delta i vår studie för att främja forskningen inom neuromodulering och få €70 rabatt på din enhet.

* Tar mindre än 2 minuter att fylla i.

Få €70 i rabatt

References

1. Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371


2. Verbanck et al 2021 / Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Frontiers in Neurology and Neuroscience Research, 2, Article 100011. https://quintet.no/wp-content/uploads/2023/11/transcutaneous-auricular-vagus-nerve[…]ifestations-of-the-long-covid-syndrome-a-pilot-study-100011.pdf


3. Dolcini et al 2025 / Dolcini, G., Favretti, M., Franculli, D., Buoncuore, G., Pellegrino, G., Di Carlo, M., Sarzi-Puttini, P., Conti, F., Iannuccielli, C., & Di Franco, M. (2025). Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clinical and experimental rheumatology, 43(6), 1095–1104. https://doi.org/10.55563/clinexprheumatol/johqvo


4. Mbikyo et al 2024 / Mbikyo, M. B., Wang, A., Ma, Q., Miao, L., Cui, N., Yang, Y., Fu, H., Sun, Y., & Li, Z. (2024). Low-Level Tragus Stimulation Attenuates Blood Pressure in Young Individuals With Hypertension: Results From a Small–Scale Single–Blind Controlled Randomized Clinical Trial. Journal of the American Heart Association, 13(19), e032269. https://doi.org/10.1161/JAHA.123.032269


5. Thakkar et al 2023 / Thakkar, V. J., Richardson, Z. A., Dang, A., & Centanni, T. M. (2023). The effect of non-invasive vagus nerve stimulation on memory recall in reading: A pilot study. Behavioural brain research, 438, 114164. https://doi.org/10.1016/j.bbr.2022.114164


6. Dasari et al 2023 / University of Oklahoma Health Sciences Center / Dasari, T. W., Akhtar, K. H., Amil, F., Zhao, Y. D., Sohinki, D., Po, S. (2023). Effects of low level tragus stimulation on inflammation in acute decompensated heart failure. Journal of Cardiac Failure. 29(4): 660–661. https://doi.org/10.1016/j.cardfail.2022.10.278


7. Jackowska et al 2022 / Jackowska, M., Koenig, J., Vasendova, V., & Jandackova, V. K. (2022). A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults. Autonomic neuroscience : basic & clinical, 240, 102972. https://doi.org/10.1016/j.autneu.2022.102972


8. Stavrakis et al 2024 / University of Oklahoma Health Sciences Center / Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Abideen Asad, Z. U., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial. JACC. Clinical electrophysiology, 10(2), 346–355. https://doi.org/10.1016/j.jacep.2023.10.015

Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com